An intellectually stimulating lifestyle is key to fighting Huntington's disease, finds study
An intellectually active lifestyle—in other words, the so-called cognitive reserve—has a protective effect on the progression and severity of the symptoms of motor, cognitive and psychiatric ...
BioSpace2d
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...
uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License ...
News Medical on MSN8d
Heart medication may slow the progression of Huntington's disease
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
MedPage Today on MSN9d
Beta-Blockers Tied to Delayed Huntington's Disease Progression
The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...
uniQure’s AMT-130 Gene Therapy for Huntington’s Disease: A Promising Pathway to Accelerated Approval
William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.Pick the best stocks and ...
The Irish News on MSN8d
New therapy for Huntington’s disease ‘may slow progression’
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the fatal illness. Huntington’s is an inherited condition that is caused by a ...
BioPharma Dive2d
UniQure shares soar on chance of speedy approval for Huntington’s therapy
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
Optimistic Buy Rating for uniQure Amid Positive Regulatory Milestone and Promising AMT-130 Results in Huntington’s Disease
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on QURE stock, giving a Buy rating today.Pick the best stocks and ...
manilatimes3d
Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial
Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 ...
Common heart drug may slow progression of Huntington's disease
A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...